Alnylam's longer-term RNAi treatment lowers blood pressure in mid-stage study - Endpoints News

cara-untuksehat.blogspot.com

One to two dos­es of an RNA in­ter­fer­ence treat­ment de­vel­oped by Al­ny­lam Phar­ma­ceu­ti­cals re­duced blood pres­sure for six months in a mid-stage clin­i­cal tri­al, ac­cord­ing to new re­search pre­sent­ed this week­end at a med­ical meet­ing.

Al­ny­lam’s goal is to de­vel­op the treat­ment, zilebe­sir­an, in­to an add-on or al­ter­na­tive to cur­rent blood pres­sure med­ica­tions, which are meant to be tak­en every day. The com­pa­ny pre­vi­ous­ly shared in Sep­tem­ber that the study had met its pri­ma­ry goal, and this week­end’s re­sults of­fered new de­tails.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Adblock test (Why?)

Alnylam's longer-term RNAi treatment lowers blood pressure in mid-stage study - Endpoints News
Read More


Bagikan Berita Ini